Type of Cancer
Lung
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.